Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H25N3O5S.3H2O |
Molecular Weight | 437.5101 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1([H])[C@]2([H])[C@@]([H])([C@@]([H])(C)O)C(=O)N2C(=C1S[C@@]3([H])C[C@@]([H])(C(=O)N(C)C)NC3)C(=O)O.O.O.O
InChI
InChIKey=CTUAQTBUVLKNDJ-OBZXMJSBSA-N
InChI=1S/C17H25N3O5S.3H2O/c1-7-12-11(8(2)21)16(23)20(12)13(17(24)25)14(7)26-9-5-10(18-6-9)15(22)19(3)4;;;/h7-12,18,21H,5-6H2,1-4H3,(H,24,25);3*1H2/t7-,8-,9+,10+,11-,12-;;;/m1.../s1
Molecular Formula | C17H25N3O5S |
Molecular Weight | 383.4642 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.htmlCurator's Comment:: description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |
Sources: https://web.archive.org/web/20161209014344/http://www.ds-pharma.com:80/rd/new_value/meropen.html
Curator's Comment:: description was created based on several sources, including
http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s036lbl.pdf |
Meropenem (generic name: meropenem hydrate) is a carbapenem antibiotic for injection showing a strong antibacterial activity to a wide range of bacteria strains from Gram-positive bacteria, Gram-negative bacteria to anaerobic bacteria. It is used as single agent therapy for the treatment of the following infections: complicated skin and skin structure infections due to Staphylococcus aureus (b-lactamase and non-b-lactamase producing, methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci. This drug also used in case of Intra-abdominal Infections for the treatment complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. In addition is used the treatment of bacterial meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (b-lactamase and non-b-lactamase-producing isolates), and Neisseria meningitides. The bactericidal activity of meropenem results from the inhibition of cell wall synthesis. Meropenem readily penetrates the cell wall of most Gram-positive and Gram-negative bacteria to reach penicillin-binding-protein (PBP) targets. Its strongest affinities are toward PBPs 2, 3 and 4 of Escherichia coli and Pseudomonas aeruginosa; and PBPs 1, 2 and 4 of Staphylococcus aureus. Meropenem has significant stability to hydrolysis by β-lactamases, both penicillinases and cephalosporinases produced by Gram-positive and Gram-negative bacteria. Meropenem should not be used to treat methicillin-resistant Staphylococcus aureus (MRSA) or methicillin-resistant Staphylococcus epidermidis (MRSE). Meropenem product with such superior effectiveness and safety has been approved for marketing by 100 countries or more in the world (as of March 2004) since its first launch in Italy in 1994.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2354204 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | MERREM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date8.3531517E11 |
|||
Primary | MERREM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date8.3531517E11 |
|||
Curative | MERREM Approved UseTo reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection, USP (I.V.) and other antibacterial drugs, Meropenem for injection, USP (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for injection, USP (I.V.) is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1), (1.2) or (1.3); Dosage and Administration (2.3), Adverse Reactions (6.1), and Clinical Pharmacology (12.3). Meropenem for injection (I.V.) is a penem antibacterial indicated as single agent therapy for the treatment of: Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) Complicated intra-abdominal infections (adult and pediatric patients). (1.2) Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for injection (I.V.) and other antibacterial drugs, Meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species. 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species. 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis., 1.1 Skin and Skin Structure Infections (Adult Patients and Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated skin and skin structure infections due to Staphylococcus aureus (methicillin-susceptible isolates only), Streptococcus pyogenes, Streptococcus agalactiae, viridans group streptococci, Enterococcus faecalis (vancomycin-susceptible isolates only), Pseudomonas aeruginosa, Escherichia coli, Proteus mirabilis, Bacteroides fragilis, and Peptostreptococcus species., 1.2 Intra-abdominal Infections (Adult and Pediatric Patients) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of complicated appendicitis and peritonitis caused by viridans group streptococci, Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Bacteroides fragilis, B. thetaiotaomicron, and Peptostreptococcus species., 1.3 Bacterial Meningitis (Pediatric Patients 3 Months of age and older only) Meropenem for injection, USP (I.V.) is indicated as a single agent therapy for the treatment of bacterial meningitis caused by Streptococcus pneumoniae ‡, Haemophilus influenzae, and Neisseria meningitidis. ‡ The efficacy of meropenem as monotherapy in the treatment of meningitis caused by penicillin nonsusceptible isolates of Streptococcus pneumoniae has not been established. Meropenem for injection, USP (I.V.) has been found to be effective in eliminating concurrent bacteremia in association with bacterial meningitis. Launch Date8.3531517E11 |
PubMed
Title | Date | PubMed |
---|---|---|
[Antibiotic therapy of cystic fibrosis in children]. | 2001 |
|
[Antimicrobial activities of meropenem against clinically isolated strains in 1999]. | 2001 Apr |
|
[Antimicrobial activities and mechanisms of carbapenem resistance in clinical isolates of carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp]. | 2001 Aug |
|
Antimicrobial susceptibility of potentially pathogenic halophilic vibrios isolated from seafood. | 2001 Aug |
|
Meropenem and continuous renal replacement. | 2001 Aug |
|
Survey of antibiotic resistance in Pseudomonas aeruginosa by The Tokyo Johoku Association of Pseudomonas Studies. | 2001 Dec |
|
Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. | 2001 Dec |
|
Unit differences in pathogen occurrence arising from the MYSTIC program European database (1997-2000). | 2001 Dec |
|
Antimicrobial resistance trends in medical centers using carbapenems: report of 1999 and 2000 results from the MYSTIC program (USA). | 2001 Dec |
|
Determining the value of antimicrobial surveillance programs. | 2001 Dec |
|
MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) conference. Hamburg, Germany, 10 May 2001. | 2001 Dec |
|
In-vitro activities of various antibiotics, alone and in combination with amikacin against Pseudomonas aeruginosa. | 2001 Dec |
|
[Microbiological monitoring of the microbic strain stability to antibacterial preparations in surgical in-patient clinics]. | 2001 Feb |
|
[In vitro and in vivo activities of panipenem against penicillin-resistant Streptococcus pneumoniae]. | 2001 Jul |
|
Case report: recovery from persistent septicemic melioidosis. | 2001 Jul |
|
Occupational allergic contact dermatitis from meropenem. | 2001 Jul |
|
Antimicrobial susceptibility patterns of enterococci in intensive care units in Sweden evaluated by different MIC breakpoint systems. | 2001 Jul |
|
Comparative in vitro antimicrobial activity of a new carbapenem, E1010, and tentative disc diffusion test interpretative criteria. | 2001 Jul |
|
Crystal structures of the class D beta-lactamase OXA-13 in the native form and in complex with meropenem. | 2001 Jul 20 |
|
Use of broad spectrum antibiotics in six non-university Swiss hospitals. | 2001 Jul 28 |
|
Ertapenem: a new carbapenem. | 2001 Jun |
|
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). III. Secular changes in susceptibility]. | 2001 Jun |
|
Treatment of nosocomial pneumonia: an experience with meropenem. | 2001 Jun |
|
Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. | 2001 Jun |
|
Resistance to antibiotics and biocides among non-fermenting Gram-negative bacteria. | 2001 Jun |
|
A rapid, sensitive high performance liquid chromatographic method for the determination of meropenem in pharmaceutical dosage form, human serum and urine. | 2001 Jun |
|
[Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1999). I. Susceptibility distribution]. | 2001 May |
|
Epidemiologic Study of Pseudomonas aeruginosa in critical patients and reservoirs. | 2001 May-Jun |
|
[A case of eosinophilic pneumonia possibly due to ifenprodil]. | 2001 Nov |
|
Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): more alike than different! | 2001 Nov |
|
In vitro and in vivo activities of meropenem and comparable antimicrobial agents against Haemophilus influenzae, including beta-lactamase-negative ampicillin-resistant strains. | 2001 Nov |
|
National shortages of antimicrobial agents: results of 2 surveys from the Infectious Diseases Society of America Emerging Infections Network. | 2001 Nov 1 |
|
Influence of in-vivo endotoxin liberation on anti-anaerobic antimicrobial efficacy. | 2001 Oct |
|
Frequency of isolation and antimicrobial resistance of gram-negative and gram-positive bacteria from patients in intensive care units of 25 European university hospitals participating in the European arm of the SENTRY Antimicrobial Surveillance Program 1997-1998. | 2001 Sep |
|
Effect of meropenem on disposition kinetics of valproate and its metabolites in rabbits. | 2001 Sep |
|
Isolation and culture of airway epithelial cells from chronically infected human lungs. | 2001 Sep |
|
Characterization of paired mucoid/non-mucoid Pseudomonas aeruginosa isolates from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. | 2001 Sep |
|
Synthesis and biological properties of new 1beta-methylcarbapenems containing heteroaromatic thioether moiety. | 2001 Sep 3 |
|
Novel mechanism of hydrolysis of therapeutic beta-lactams by Stenotrophomonas maltophilia L1 metallo-beta-lactamase. | 2001 Sep 7 |
|
Comparative in vitro activity of isepamicin and other antibiotics against gram-negative bacilli from intensive care units (ICU) in Belgium. | 2001 Sep-Oct |
|
Effects of cefepime and meropenem on the gastrointestinal colonization of surgical patients by Candida albicans. | 2001 Sep-Oct |
|
Use of Etests with carbapenems for Gram-negative rods producing beta-lactamases. | 2002 Feb |
|
Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients. | 2002 Feb |
|
Carbapenem-resistant Acinetobacter and role of curtains in an outbreak in intensive care units. | 2002 Feb |
|
In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. | 2002 Feb |
|
Meropenem stability to beta-lactamase hydrolysis and comparative in vitro activity against several beta-lactamase-producing Gram-negative strains. | 2002 Feb |
|
Acute necrotizing gastritis by Escherichia coli in a severely neutropenic patient. | 2002 Jan |
|
Antimicrobial susceptibilities among clinical isolates of extended-spectrum cephalosporin-resistant Gram-negative bacteria in a Taiwanese University Hospital. | 2002 Jan |
|
Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). | 2002 Mar |
|
Antibiotic-resistant gram-negative organisms in pediatric chronic-care facilities. | 2002 Mar 15 |
Sample Use Guides
Adult Patients: The recommended dose of MERREM I.V. is 500 mg given every 8 hours for skin and skin structure infections and 1 gram given every 8 hours for intra-abdominal infections. When treating complicated skin and skin structure infections caused by P.aeruginosa, a dose of 1 gram every 8 hours is recommended.
Pediatric Patients 3 Months of Age and Older: For pediatric patients 3 months of age and older, the MERREM I.V. dose is 10 mg/kg, 20 mg/kg or 40 mg/kg every 8 hours (maximum dose is 2 grams every 8 hours), depending on the type of infection (complicated skin and skin structure, intra-abdominal or meningitis). Pediatric patients weighing over 50 kg should be administered MERREM I.V. at a dose of 500 mg every 8 hours for complicated skin and skin structure infections, 1 gram every 8 hours for intra-abdominal infections and 2 grams every 8 hours for meningitis. MERREM I.V. should be given as intravenous infusion over approximately 15 minutes to 30 minutes or as an intravenous bolus injection (5 mL to 20 mL) over approximately 3 minutes to 5 minutes. There is limited safety data available to support the administration of a 40 mg/kg (up to a maximum of 2 grams) bolus dose.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9126699
Curator's Comment:: Meropenem was 4-64 times more active than imipenem against gram-negatives, including Enterobacteriaceae organisms, Pseudomonas aeruginosa, Burkholderia cepacia, Neisseria meningiditis, and Haemophilus influenzae. Imipenem was up to 2-4 times more active than meropenem against some gram-positive cocci, including Enterococcus faecalis. Meropenem, unlike imipenem or ceftazidime, was bactericidal for all strains of Enterobacteriaceae, P. aeruginosa, and gram-positive cocci tested at < or = 8 times the MIC.
Unknown
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:03:14 UTC 2021
by
admin
on
Fri Jun 25 21:03:14 UTC 2021
|
Record UNII |
FV9J3JU8B1
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QJ01DH02
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
||
|
NCI_THESAURUS |
C260
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
||
|
NDF-RT |
N0000175496
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
||
|
WHO-ATC |
J01DH02
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
||
|
WHO-ATC |
J01DH52
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
||
|
FDA ORPHAN DRUG |
130799
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
||
|
LIVERTOX |
604
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
441129
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
1392454
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | USP-RS | ||
|
DB00760
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
MEROPENEM
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
Meropenem
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
CHEMBL127
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
FV9J3JU8B1
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
M7240
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | Merck Index | ||
|
SUB21617
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
119478-56-7
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
C059500
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
1709
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
29561
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | RxNorm | ||
|
C1160
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY | |||
|
119478-56-7
Created by
admin on Fri Jun 25 21:03:15 UTC 2021 , Edited by admin on Fri Jun 25 21:03:15 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
||
|
TRANSPORTER -> SUBSTRATE | |||
|
EXCRETED UNCHANGED |
Meropenem: approximately 40–60% of dose was excreted unchanged within 24 to 48 hours with a further 28% recovered as the microbiologically inactive hydrolysis product; fecal elimination accounts for ~2% of dose.
|
||
|
PARENT -> SALT/SOLVATE | |||
|
TRANSPORTER -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
correction factor: for the calculation of content, multiply the peak area of impurity A by 1.6
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||